Fingolimod Modulation of T-Cell Subsets in ALS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Amyotrophic Lateral Sclerosis (ALS) are inadequate, particularly for the sporadic form where the mechanism of disease pathology is unknown, and existing therapies do not effectively address the neuroinflammatory processes contributing to the progression of the disease.
Innovation Solution
Administration of sphingosine1-phosphate receptor modulators, such as fingolimod, which inhibit macrophage accumulation and reduce lymphocyte proliferation, including CD8+ and CD4+ T cell populations, to modulate neuroinflammatory processes and treat ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infiltrating T cell populations are present in ALS, then neuroprotective effect is observed, but if CD8+ T cells infiltrate, then progressive neurodegeneration is contributed
Solution Approach 1:
The patent applies local quality by selectively depleting only CD8+ T cells while preserving other T cell populations (CD4+ T cells, regulatory T cells) that provide neuroprotective effects. This selective approach allows the therapy to eliminate harmful CD8+ T cells locally in the CNS while maintaining the beneficial immune environment through preservation of other lymphocyte subsets.
Solution Approach 2:
The patent inverts the conventional understanding by targeting specific T cell subsets rather than using broad immunosuppression. Instead of suppressing all immune cells, the invention uses selective depletion of CD8+ T cells, thereby inverting the approach from non-specific immunosuppression to specific immune modulation that preserves neuroprotective mechanisms.
2Reliability
If sphingosine1-phosphate receptor modulators are administered, then lymphocyte proliferation is reduced and macrophage accumulation is inhibited, but device complexity and treatment specificity requirements increase
Solution Approach 1:
The patent uses sphingosine1-phosphate receptor modulators as intermediary molecules that indirectly achieve selective CD8+ T cell depletion. Rather than directly targeting CD8+ T cells, the compound modulates sphingosine1-phosphate receptors on lymphocytes, causing sequestration in lymph nodes and secondary lymphoid organs, thereby indirectly depleting CD8+ T cells from the CNS while requiring manageable treatment protocols.
3Ease of operation
If existing ALS therapies are used, then treatment is provided, but they do not effectively address neuroinflammatory processes contributing to disease progression
Solution Approach 1:
The patent applies parameter changes by modifying the immune system's composition and activity through sphingosine1-phosphate receptor modulation. This changes key parameters including lymphocyte distribution, CD8+ T cell proliferation rates, and macrophage accumulation, thereby transforming the therapeutic approach from symptomatic management to disease-modifying treatment that addresses underlying neuroinflammatory processes.
Data Source
AI summary
Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.